9 articles with TechnoVax Inc.
TechnoVax, Inc. has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
TechnoVax Inc. Awarded National Institutes of Health (NIH) Grant To Develop A VLP Based Respiratory Syncytial Virus (RSV) Vaccine
TechnoVax Inc. Awarded National Institutes of Health (NIH) Grant to Develop a Universal Flu Vaccine Based on Its Virus-Like-Particle (VLP) Technology
TechnoVax Inc. Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program
TechnoVax Inc. Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate